grant
Tuning KITv CAR T cells for the solid tumor environment
Organization SLOAN-KETTERING INST CAN RESEARCHLocation NEW YORK, UNITED STATESPosted 13 Aug 2024Deadline 31 Jul 2029
NIHUS FederalResearch GrantFY2025AddressAntigen TargetingAntigensApoptosisApoptosis PathwayAvidityB7-H1BB2BindingBiologicalBone-Derived Transforming Growth FactorBronchopulmonary SequestrationC-KIT MutationCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCD117 MutationCD274CD28CD28 geneCD54CD8CD8BCD8B1CD8B1 geneCancersCell BodyCell Communication and SignalingCell SignalingCell TherapyCellsCheckpoint inhibitorClinicalClinical TrialsDNA mutationDominant Negative ReceptorDoseEnvironmentGenetic ChangeGenetic defectGenetic mutationHelper CellsHelper T-CellsHelper T-LymphocytesHelper-Inducer T-CellsHelper-Inducer T-LymphocyteHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerICAM-1 GeneICAM1ICAM1 geneIFN-GammaIFN-gIFN-γIFNGIFNγImmune InterferonImmune checkpoint inhibitorImmune responseImmunosuppressionImmunosuppression EffectImmunosuppressive EffectInducer CellsInducer T-LymphocytesInfiltrationInfusionInfusion proceduresInterferon GammaInterferon Type IIIntracellular Communication and SignalingInvestigationInvestigatorsKeytrudaLYT3LytotoxicityMacrophageMalignant CellMalignant Hematologic NeoplasmMalignant Mesothelioma of the PleuraMalignant NeoplasmsMalignant Pleural MesotheliomaMalignant Pleural NeoplasmMalignant Pleural TumorMalignant TumorMediatingMethodsMilk Growth FactorModelingMolecular InteractionMutationMφPD 1PD-1PD-1 antibodyPD-L1PD1PD1 antibodyPDL-1Pathway interactionsPatientsPhase 1/2 trialPhase I/II TrialPlatelet Transforming Growth FactorPleura CancerPleural CancerProgrammed Cell DeathProgrammed Cell Death 1 Ligand 1Programmed Death Ligand 1ProliferatingPulmonary SequestrationReagentReceptor ProteinReportingResearch PersonnelResearchersSafetySignal TransductionSignal Transduction SystemsSignalingSolid NeoplasmSolid TumorSoluble Mpf/Mesothelin-Related ProteinStressSurvivorsSynapsesSynapticT cell receptor based immunotherapyT cell receptor cellular immunotherapyT cell receptor engineered therapyT cell receptor immunotherapyT cells for CART-Cell ProliferationT-Cell Receptor TherapyT-Cell Receptor TreatmentT-Cell Receptor based TherapyT-Cell Receptor based TreatmentT-CellsT-LymphocyteT44TCR T cell immunotherapyTCR T cell therapyTCR TherapyTCR based T cell immunotherapyTCR based TherapyTCR based immune therapyTCR based immunotherapyTCR based treatmentTCR immunotherapyTGF BTGF-betaTGF-βTGFbetaTGFβToxic effectToxicitiesTransforming Growth Factor betaTransforming Growth Factor-Beta Family GeneTranslatingTranslationsTumor CellTumor PromotionUpregulationaPD-1aPD1anti programmed cell death 1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyantiPD-1biologicbiological signal transductioncancer cellcancer microenvironmentcell based interventioncell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular therapeuticcellular therapycheck point blockadecheckpoint blockadechimeric antigen T cell receptorchimeric antigen receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellscytotoxiccytotoxicityexhaustiongenome mutationhost responseimmune check point blockadeimmune check point inhibitorimmune checkpoint blockadeimmune suppressionimmune suppressive activityimmune suppressive functionimmune system responseimmunogenimmunoresponseimmunosuppressive activityimmunosuppressive functionimmunosuppressive responsein vivoinfusionsinnovateinnovationinnovativekinase inhibitorlFN-Gammamalignancymalignant pleura neoplasmmalignant pleura tumormesothelinneoplasm/cancerneoplastic celloverexpressoverexpressionpathwaypembrolizumabperipheral bloodphase 1 trialphase I trialprogrammed cell death 1programmed cell death ligand 1programmed cell death protein 1programmed cell death protein ligand 1programmed death 1protein death-ligand 1receptorsle2successsynapsesystemic lupus erythematosus susceptibility 2thymus derived lymphocytetranslationtumortumor microenvironmentαPD-1αPD1
Description preview
PROJECT ABSTRACT
We developed and translated CD28 costimulated chimeric antigen receptor (M28z CARs) T cells that target mesothelin
(MSLN), a cancer-associated antigen that is overexpressed in a majority of solid tumors; 65 patients have been treated in
phase I/II trials, with no on-target, off-tumor toxicity. Having demonstrated that regionally…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click